TREM2 and ovarian neoplasm: Further investigation into TREM2 as a potential clinical target has culminated in a clinical trial testing the efficacy of a humanized TREM2 targeting antibody in unresectable or metastatic breast, colorectal, lung, renal, and ovarian tumors after relapse following standard of care treatment.174